Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 7/20 | 0.45 |
| ▸ | FGF1 | P05230 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 4/20 | 0.37 |
| ▸ | SI | P14410 | 4/20 | 0.37 |
| ▸ | PYGB | P11216 | 1/20 | 0.37 |
| ▸ | AMY2A | P04746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10781125 | 0.86 | LGALS8 (0.57) | LGALS8FGF1PYGBL3MBTL1GAA | |
| SCHEMBL13151561 | 0.86 | LGALS8 (0.57) | LGALS8FGF1PYGBL3MBTL1GAA | |
| SCHEMBL15095565 | 0.86 | LGALS8 (0.57) | LGALS8FGF1PYGBL3MBTL1GAA | |
| SCHEMBL13180919 | 0.86 | LGALS8 (0.57) | LGALS8FGF1PYGBL3MBTL1GAA | |
| SCHEMBL25505097 | 0.86 | LGALS8 (0.57) | LGALS8FGF1PYGBL3MBTL1GAA | |
| SCHEMBL10781121 | 0.86 | LGALS8 (0.57) | LGALS8FGF1PYGBL3MBTL1GAA | |
| SCHEMBL14010636 | 0.86 | LGALS8 (0.57) | LGALS8FGF1PYGBL3MBTL1GAA | |
| SCHEMBL14084324 | 0.86 | LGALS8 (0.49) | LGALS8FGF1MGAMSIPYGB | |
| SCHEMBL10176392 | 0.85 | LGALS8 (0.45) | LGALS8FGF1MGAMSIAMY2A | |
| SCHEMBL20109869 | 0.85 | LGALS8 (0.45) | LGALS8FGF1MGAMSIAMY2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9387252-B2 | Pharmaceutical compositions with enhanced performance | BEND RESEARCH, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-8940800-B2 | Pharmaceutical compositions with enhanced performance | BEND RESEARCH, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140171441-A1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE | BEND RESEARCH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20120264833-A1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE | LONZA BEND INC. | 2012-10-18 | — | — | US | disclosed |
| US-8207232-B2 | Pharmaceutical compositions with enhanced performance | BEND RESEARCH, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20080262107-A1 | A solid amorphous dispersion of a low-soluble drug and hydroxypropylmethyl celllulose acetate succinate with an ester degree of substitution of 0.85 which results in concentration-enhancement, time release agents, and storage stability; rapid crystal growth inhibitors in supersaturated aqueous solutions | PFIZER PRODUCTS INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080064763-A1 | solid amorphous dispersions of low-solubility drugs and hydroxypropyl methyl cellulose alkanyl phthalate; enhance physical stability, absorption of drug in vivo, drug's bioavailability; fluvastatin HMG-CoA reductase inhibitor | BEND RESEARCH, INC. | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064763-A1 | solid amorphous dispersions of low-solubility drugs and hydroxypropyl methyl cellulose alkanyl phthalate; enhance physical stability, absorption of drug in vivo, drug's bioavailability; fluvastatin HMG-CoA reductase inhibitor | HMGCR, CYP3A43, CYP4F3 | LGALS8 3107/4885FGF1 346/4885MGAM 420/4885 |
| US-20140171441-A1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE | CYP3A43, CYP3A7, CYP3A4 | LGALS8 1186/4885FGF1 1437/4885MGAM 20/4885 |
| US-20080262107-A1 | A solid amorphous dispersion of a low-soluble drug and hydroxypropylmethyl celllulose acetate succinate with an ester degree of substitution of 0.85 which results in concentration-enhancement, time release agents, and storage stability; rapid crystal growth inhibitors in supersaturated aqueous solutions | HPD, HAAO, SUCLA2 | LGALS8 2915/4885FGF1 973/4885MGAM 4/4885 |
| US-20120264833-A1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE | HPD, HAAO, MCCC2 | LGALS8 1999/4885FGF1 3012/4885MGAM 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.